Top 5 Groundbreaking CAR T-Cell Therapies Advancing the Fight Against Multiple Myeloma

June 26, 2025

The field of chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma is undergoing transformative progress, propelled by the urgent demand for solutions in relapsed or treatment-resistant patients. As innovations in cell and gene therapy for multiple myeloma continue to accelerate, several standout candidates are emerging, each with the potential to redefine current treatment paradigms.

5 Promising CAR T-cell Therapies for Multiple Myeloma to Watch

Zevorcabtagene Autoleucel (Zevor-cel): Developed by IASO Bio, this B-cell maturation antigen (BCMA)-directed CAR T therapy earned approval from China’s National Medical Products Administration (NMPA) in February 2024. Zevor-cel has demonstrated robust clinical efficacy, positioning it as a formidable entrant in the international CAR T-cell therapy arena.

Anito-cel: With FDA approval already secured, anito-cel stands out as a transformative therapy for patients with relapsed or refractory disease. Its strong response rates highlight the growing confidence in gene-driven immunotherapeutics in managing multiple myeloma.

Explore the latest developments in cell and gene therapies for multiple myeloma:
https://www.delveinsight.com/blog/car-t-cell-therapies-for-multiple-myeloma?utm_source=blog&utm_medium=promotion&utm_campaign=akpr

ARLO-CEL (arlo-cel CAR-T): Now in late-stage clinical development, arlo-cel is attracting attention for its sustained therapeutic responses and a favorable safety profile. It’s being closely watched as a potential competitor to leaders like Carvykti, especially in heavily pretreated patient populations.

CC-95266: This investigational therapy from Bristol Myers Squibb—also known as BMS BCMA CAR-T—features a unique CAR construct targeting BCMA. With ongoing clinical studies, CC-95266 represents BMS’s strategic push to maintain an edge among other Genmab competitors in the multiple myeloma landscape.

GLPG5301: Galapagos is advancing this next-generation BCMA-targeted candidate as part of its broader commitment to innovative gene therapy for hematologic cancers. GLPG5301 underscores the growing pipeline of advanced treatments targeting the underlying disease biology.

Learn more about emerging therapies reshaping myeloma treatment:
https://www.delveinsight.com/blog/car-t-cell-therapies-for-multiple-myeloma?utm_source=blog&utm_medium=promotion&utm_campaign=akpr

Future Perspective on CAR T-cell Therapies for Multiple Myeloma

As more CAR T-cell therapies for multiple myeloma reach pivotal trial milestones or secure regulatory approvals, the market is on track for significant expansion. Innovations like Zevorcabtagene Autoleucel, anito-cel, and ARLO-CEL are not only offering new hope to patients but are also setting new standards for efficacy and safety. Going forward, the spotlight will increasingly focus on improving long-term outcomes, minimizing toxicity, and enhancing patient access on a global scale.